Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer

Esophageal cancer (EC) is the seventh most common malignancy worldwide. Although systemic chemotherapy is the standard treatment for advanced EC, the available cytotoxic agents have limited efficacy. Pembrolizumab, a humanized monoclonal immunoglobulin G4 antibody that inhibits programmed cell death...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirose, Toshiharu, Yamamoto, Shun, Kato, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837289/
https://www.ncbi.nlm.nih.gov/pubmed/36644131
http://dx.doi.org/10.1177/17562848221148250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837289/
https://www.ncbi.nlm.nih.gov/pubmed/36644131
http://dx.doi.org/10.1177/17562848221148250

Ejemplares similares